The Company is continuing to focus on areas of high innovation and higher growth while maintaining its industry-leading pipeline which is expected to deliver more than 20 novel therapies and more than 50 product expansions by 20306.JNJ Sales Forecast
Next quarter's sales forecast for JNJ is $22.31B with a range of $21.90B to $22.61B. The previous quarter's sales results were $21.38B. JNJ beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.20% of the time in the same period.Valuation metrics show that Johnson & Johnson may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of C.
What is the strategy of Johnson and Johnson in 2024 : J&J's 2024 strategy will focus on newer meds to offset Stelara's patent cliff. Executives on the healthcare giant's full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.
Why is JNJ breaking up
The split allows J&J's executives to focus more on developing innovations and expanding the businesses of medical technologies and pharmaceuticals. “We need to be a top-tier medical tech company and a top-tier pharmaceutical company, first and foremost,” Chief Financial Officer Joseph Wolk said.
What is the growth potential of JNJ : Growth Prospects, Valuation & Catalyst
Reaching our target valuation by 2029 would add 3.8% to annual returns for the period. Therefore, we project that Johnson & Johnson will return 12.5% annually over the next five years due to earnings growth of 6%, a starting yield of 3.3%, and a tailwind from multiple expansion.
Johnson & Johnson stock price stood at $154.67
Year
Mid-Year
Tod/End,%
2024
$156
+1%
2025
$156
+3%
2026
$165
+12%
2027
$186
+23%
We still view the stock as undervalued, with the market not fully appreciating J&J's innovative products, which should propel long-term growth and reinforce the firm's wide moat. In the drug unit, sales grew 8% operationally (excluding covid-19 product sales), led by new-product growth.
Is JNJ dividend safe
Johnson & Johnson (JNJ 0.23%) is arguably one of the safest dividend stocks in the world. The healthcare giant generates durable cash flow and has a fortress-like balance sheet. These features put its 3.4% yielding dividend on a rock-solid foundation.J&J also narrowed its full-year guidance for the year. The company now expects sales of $88 billion to $88.4 billion. That compares with a previous forecast of $87.8 billion to $88.6 billion. J&J expects adjusted earnings of $10.57 to $10.72 per share.There is a large emphasis on maintaining a culture of health at Johnson & Johnson. The culture of health is embedded in the company credo and valuing the health and wellbeing of employees and their families is foundational to Johnson & Johnson's identity as a company. The Justice Department opened a probe into the products in July 2019, investigating what the company knew about the risk of cancer. Amid thousands of lawsuits over allegations of talc-induced health problems, Johnson & Johnson filed for bankruptcy twice, in October 2021 and April 2023.
What are analysts saying about JNJ : Analyst Price Targets
Based on analysts offering 12 month price targets for JNJ in the last 3 months. The average price target is $174 with a high estimate of $215 and a low estimate of $155.
What is Johnson and Johnson forecast for 2024 : Excluding certain items for the first quarter of 2024, adjusted earnings per share were $2.71. J&J also narrowed its full-year guidance for the year. The company now expects sales of $88 billion to $88.4 billion. That compares with a previous forecast of $87.8 billion to $88.6 billion.
Is JNJ overvalued or undervalued
Over the past twelve months the share price is down 4.28%. Based on the DCF valuation, the stock is undervalued. The DCF value of $215.94 per share is higher than the current market price of $156.41. SJ Analyst Recommendation Trends
In the current month, SJ has received 7 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. SJ average Analyst price target in the past 3 months is C$91.54.What does the J&J split mean for shareholders If you currently own shares of Johnson & Johnson, when the company splits, you will own shares of both Johnson & Johnson – which will be the new pharmaceutical/medical device business – as well as shares of Kenvue, the new consumer health business.
Is JNJ a dividend king : Johnson & Johnson has a higher credit rating than the U.S. Federal Government. The healthcare giant is in the elite class of Dividend Kings.
![Kladsko-5-malý-Karlův-Most[1]](https://www.einarstrayorchestra.com/wp-content/uploads/2024/06/Kladsko-5-maly-Karluv-Most1-1024x692-250x120.jpg)
![Stubai[1]](https://www.einarstrayorchestra.com/wp-content/uploads/2024/06/Stubai1-250x120.jpg)
Antwort What is the future of Johnson and Johnson? Weitere Antworten – What is the future of Johnson & Johnson
The Company is continuing to focus on areas of high innovation and higher growth while maintaining its industry-leading pipeline which is expected to deliver more than 20 novel therapies and more than 50 product expansions by 20306.JNJ Sales Forecast
Next quarter's sales forecast for JNJ is $22.31B with a range of $21.90B to $22.61B. The previous quarter's sales results were $21.38B. JNJ beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 46.20% of the time in the same period.Valuation metrics show that Johnson & Johnson may be undervalued. Its Value Score of B indicates it would be a good pick for value investors. The financial health and growth prospects of JNJ, demonstrate its potential to outperform the market. It currently has a Growth Score of C.
What is the strategy of Johnson and Johnson in 2024 : J&J's 2024 strategy will focus on newer meds to offset Stelara's patent cliff. Executives on the healthcare giant's full-year earnings call highlighted a strong cash position and incremental dealmaking as a way to get past incoming competition.
Why is JNJ breaking up
The split allows J&J's executives to focus more on developing innovations and expanding the businesses of medical technologies and pharmaceuticals. “We need to be a top-tier medical tech company and a top-tier pharmaceutical company, first and foremost,” Chief Financial Officer Joseph Wolk said.
What is the growth potential of JNJ : Growth Prospects, Valuation & Catalyst
Reaching our target valuation by 2029 would add 3.8% to annual returns for the period. Therefore, we project that Johnson & Johnson will return 12.5% annually over the next five years due to earnings growth of 6%, a starting yield of 3.3%, and a tailwind from multiple expansion.
Johnson & Johnson stock price stood at $154.67
We still view the stock as undervalued, with the market not fully appreciating J&J's innovative products, which should propel long-term growth and reinforce the firm's wide moat. In the drug unit, sales grew 8% operationally (excluding covid-19 product sales), led by new-product growth.
Is JNJ dividend safe
Johnson & Johnson (JNJ 0.23%) is arguably one of the safest dividend stocks in the world. The healthcare giant generates durable cash flow and has a fortress-like balance sheet. These features put its 3.4% yielding dividend on a rock-solid foundation.J&J also narrowed its full-year guidance for the year. The company now expects sales of $88 billion to $88.4 billion. That compares with a previous forecast of $87.8 billion to $88.6 billion. J&J expects adjusted earnings of $10.57 to $10.72 per share.There is a large emphasis on maintaining a culture of health at Johnson & Johnson. The culture of health is embedded in the company credo and valuing the health and wellbeing of employees and their families is foundational to Johnson & Johnson's identity as a company.
The Justice Department opened a probe into the products in July 2019, investigating what the company knew about the risk of cancer. Amid thousands of lawsuits over allegations of talc-induced health problems, Johnson & Johnson filed for bankruptcy twice, in October 2021 and April 2023.
What are analysts saying about JNJ : Analyst Price Targets
Based on analysts offering 12 month price targets for JNJ in the last 3 months. The average price target is $174 with a high estimate of $215 and a low estimate of $155.
What is Johnson and Johnson forecast for 2024 : Excluding certain items for the first quarter of 2024, adjusted earnings per share were $2.71. J&J also narrowed its full-year guidance for the year. The company now expects sales of $88 billion to $88.4 billion. That compares with a previous forecast of $87.8 billion to $88.6 billion.
Is JNJ overvalued or undervalued
Over the past twelve months the share price is down 4.28%. Based on the DCF valuation, the stock is undervalued. The DCF value of $215.94 per share is higher than the current market price of $156.41.
SJ Analyst Recommendation Trends
In the current month, SJ has received 7 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. SJ average Analyst price target in the past 3 months is C$91.54.What does the J&J split mean for shareholders If you currently own shares of Johnson & Johnson, when the company splits, you will own shares of both Johnson & Johnson – which will be the new pharmaceutical/medical device business – as well as shares of Kenvue, the new consumer health business.
Is JNJ a dividend king : Johnson & Johnson has a higher credit rating than the U.S. Federal Government. The healthcare giant is in the elite class of Dividend Kings.